Therapeutic Response

PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Capecitabine in combination with Oxaliplatin and Tislelizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description

Tevimbra (tislelizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized tislelizumab in combination with platinum and fluoropyrimidine-based chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 with a tumor area positivity (TAP) score >= 5%. This indication is based on BGB-A317-305, a global, randomized, double-blind, placebo-controlled study involving 997 patients. The chemotherapy regimen consisted of either oxaliplatin and capecitabine, or cisplatin and 5-FU.